Company intelligence / Profile preview

Somaxon Pharmaceuticals, Inc.

San Diego, California, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

Somaxon's main product Silenor (doxepin) was FDA-approved in March 2010 for the treatment of insomnia characterized by difficulty with sleep maintenance. The drug was made commercially available by prescription in the United States in September 2010. Clinical trials demonstrated maintenance of sleep, including into the seventh and eighth hours of the night, with no meaningful evidence of next day residual effects and an overall adverse events profile comparable to placebo.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

doxepin

Phase 3

Indications: Insomnia

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Somaxon Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Somaxon Pharmaceuticals, Inc..

Explore the full profile